Case Report

Testicular Inflammatory Myofibroblastic Tumor: 
A Known Entity at a Very Rare Site

Hans-Ullrich Voelker,1 Daniel Kuehn,2 Annette Strehl,1 and Stefan Kircher3

1Institute of Pathology, Leopoldina Hospital, 97422 Schweinfurt, Germany
2Department of Urology, Leopoldina Hospital, 97422 Schweinfurt, Germany
3Institute of Pathology, University of Wuerzburg, 97080 Wuerzburg, Germany

Correspondence should be addressed to Hans-Ullrich Voelker; hvoelker@leopoldina.de

Received 1 August 2017; Accepted 26 November 2017; Published 21 December 2017

Academic Editor: Bharat Rekhi

Copyright © 2017 Hans-Ullrich Voelker et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Inflammatory myofibroblastic tumors (IMT) are distinctive lesions of unknown etiology, composed of myofibroblastic spindle cells with an associated inflammatory background. They can occur in a wide age range and at all anatomic sites, but most frequently they can be observed in the lung (especially in pediatric cases), abdomen, or retroperitoneum. The urinary bladder is one of the most common sites in urological cases. We present a very rare case of IMT of the testis. Clinically, a 40-year-old patient showed a palpable painless lesion of the right testis. Ultrasound examination showed two solid intratesticular foci. During surgical intervention, the intraoperative frozen section revealed mesenchymal tumors admixed with an uncommon inflammatory infiltrate, consistent with a reorganized abscess. Despite the benign result, orchiectomy was performed due to the multifocal presentation and the large size of 3 cm. The final diagnosis was IMT without ALK-rearrangement. Incomplete resection increases the risk of local relapses to 30%. In this case, a complete resection could be achieved and the patient is free of tumor 15 months later.

1. Introduction

Inflammatory myofibroblastic tumors (IMT), formerly known as plasma cell granuloma or inflammatory pseudotumor, are rare benign tumors which can occur at all anatomic sites. The most frequent location in pediatric cases is the lung, whereas in adults IMT are often located in the abdomen or retroperitoneum. Manifestations at uncommon sites are also possible, for example, in the larynx [1, 2]. In urological cases, IMT mostly affect the urinary bladder and are sometimes associated with a history of preceding iatrogenic manipulation [3]. Despite the wide possible range of patient age and anatomic distribution, IMT is a rare entity. The etiology remains unclear. Around 50% of IMT show a clonal rearrangement of the ALK gene (2p23, anaplastic lymphoma kinase). ALK-negative tumors are more often found in elderly patients and show a higher degree of cytological pleomorphism and mitotic activity as well as a higher risk for local relapses, especially after incomplete surgical resection [4]. Because some patients can benefit from treatment with both steroidal and nonsteroidal antiinflammatory medication, an aberrant inflammatory response was assumed to be important for pathogenesis, in combination with a true neoplastic nature of the disease. Therapy of choice is a complete excision.

Microscopic examination shows a mesenchymal tumor dominated by well demarcated fascicular proliferations of myofibroblastic spindle cells admixed with plasma cells, lymphocytes, and histiocytes. Additional immunohistochemical investigations can be helpful for the correct diagnosis due to a wide spectrum of morphological variants. These tumors present a pitfall during intraoperative frozen section due to the wide spectrum of possible mimics ranging from simple reactive postinflammatory changes to true spindle cell tumors.

2. Case Presentation

A 40-year-old patient (nonsmoker, no other complaints) reported painless palpable lesions of the left and right
positive. CD30 was expressed in isolated activated cells of B-lymphocytes (CD20 positive) than T-lymphocytes (CD5 and EMA. Among inflammatory cells, there were less B-lymphocytes (CD20 positive) than T-lymphocytes (CD5 positive). CD30 was expressed in isolated activated cells without atypical morphology; CD56 displayed loosely distributed ganglion-like cells. ALK-1 was not expressed. The plasma cell population (CD138+) did not show a significant overgrowth with IgG4+ cells. Proliferative activity (MiB-1) was not significantly increased. Additionally, for safety PLAP stains were done despite absence of suspicious changes within seminiferous tubules. Additional germ cell neoplasia in situ was excluded by negative stain for PLAP. Some examples are given in Figure 2.

All stains and technical processes were performed according to routine protocols (Autostainer Bond Max, Leica). Antibodies were tested using suitable positive controls according to the manufacturer’s recommendation. EBER (EBV-encoded RNA) in situ hybridization was performed (EBER probe Y-5200, PNA-ISH-Detection Kit K-5201, Dako) with a negative result.

FISH-analysis demonstrated a lack of ALK-gene (2p23.3) alterations in 97% of the cells using an ALK break-apart probe, corresponding to a negative result. In approximately 34% of cells only one colocalization signal could be observed. A negative result was also noted using a ROSI break-apart probe where 98% of cells showed no evidence of gene-rearrangement in the ROSI-gene (6q22). In 17% of cells, a gain of up to 4 colocalization signals could be observed, whereas 27% displayed only one colocalization signal.

In conclusion, final diagnosis of inflammatory myofibroblastic tumor (IMT) of the right testis was established, with two separate foci 3 cm apart and associated moderate chronic inflammatory changes as well as fibrosis with secondary cystic change of the epididymis. The diagnosis was confirmed by a second opinion at the Institute of Pathology of the University of Wuerzburg (Director: Professor Dr. med. A. Rosenwald).

3. Discussion

Inflammatory myofibroblastic tumor (IMT) is a benign tumorous proliferation of myofibroblastic spindle cells accompanied by a mixed chronic inflammatory infiltrate consisting of plasma cells and lymphocytes. The clinical presentation with suspicion for malignancy is not uncommon and fast-growing processes are possible. In some cases large tumors are locally aggressive with destruction of adjacent structures [2]. The etiology of IMT remains unknown, a review of the relevant literature suggesting more than one possible pathway of pathogenesis: a more truly neoplastic pathway in ALK-positive cases and a nonneoplastic reactive pathway secondary to inflammation in ALK-negative cases.

A possible stimulation of proliferative activity as a result of autoimmune processes has also been discussed [5]. Despite the wide range of possible anatomic locations, most tumors were detected in the lung, the abdomen, or the retroperitoneum [4]. A few case reports describe lesions of the paratesticular soft tissue or spermatic cord [6–9]. Intratesticular manifestation is very rare, with only three reports existing [10–12]. In all these cases solitary tumors were observed, whereas we could verify two separate manifestations in the same testis. In our case report no medical history of relevant recurrent inflammatory diseases of the scrotum, epididymis,
Case Reports in Urology

Figure 2: Histology and immunohistochemistry: (a) HE ×200, (b) positivity for sm-actin, ×200, (c) few T-cells in CD5, ×200, (d) scattered B-cells in CD20, ×200, (e) also scattered plasma cells in CD138, negative for IgG4 (not shown), ×200, and (f) very low proliferation, Ki67, ×200.

or testis existed; furthermore the patient did not specify previous trauma or other relevant diseases (e.g., hernia, undescended testis, and extreme sportive activity). Hematological investigations did not reveal any pathological findings, especially no signs of persistent inflammation with elevation of leucocytes or CRP. However, the microscopically evident moderate chronic unspecific inflammation and fibrosis of the epididymis could be seen as an indication of an underlying reactive pathogenesis.

Even though epididymitis with consecutive orchitis is a common occurrence in elderly patients, there are only very few reports of additional IMT at this site. In the majority of cases a purely reactive lesion seems unlikely. Molecular studies could detect genetic aberrations including a clonal origin, chromosomal abnormalities involving 2p23, fusion of the ALK gene with tropomyosin 3 (TPM3-ALK) or tropomyosin 4 (TPM4-ALK), translocations of ROS1 gene, RET mutations, or alterations using comparative genomic analysis CGH [2, 13–16]. In this setting, the morphologic subtypes defined by Coffin et al. (nodular fasciitis-like, fibrous histiocytoma-like, and collagen dense with a pattern similar to desmoid fibromatosis) could represent cases of true neoplastic nature rather than reactive lesions with “plasma cell granuloma” at one end of the spectrum. The latter could conversely be triggered by an atypical autoimmune response. The importance of Alk-1 expression for distinction between neoplastic and reactive etiology remains unclear. Anaplastic lymphoma kinase (Alk-1) expression is mostly detectable in
IMFTs of patients under 40 years. Therefore, the hypothesis of a postinflammatory or traumatic origin could become important if the majority of Alk-1 negative cases were found to represent the nonneoplastic reactive variant. This could explain why Coffin et al. described a recurrence rate of 45% in Alk-positive and only 20% of Alk-negative pulmonary and extrapulmonary IMT [4]. Our case was negative for both ALK and ROS1.

Despite the often benign clinical course, local recurrence is possible, whereas the metastatic potential seems very low [4]. Cases with metastasis are rare and to our knowledge the relevant literature gives no evidence of true metastasis [4]. Cases with metastasis are rare and to our knowledge the relevant literature gives no evidence of true metastasis [4].

4. Conclusion

IMT is a rare entity, which needs special efforts of pathologist. The differential diagnosis of IMT comprises low grade myofibroblastic sarcomas as well as a long list of benign, reactive, or neoplastic spindle cell lesions, such as leiomyoma, solitary fibrous tumor, spindle cell carcinoma, nodular fasciitis, peripheral nerve sheath tumor, and sex cord stromal tumors. Morphology and immunohistochemical profile are helpful in ruling out these entities also at uncommon anatomic sites like testis. Complete excision is the therapy of choice.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

[1] H.-U. Völker, M. Scheich, S. Höller et al., “Differential diagnosis of laryngeal spindle cell carcinoma and inflammatory myofibroblastic tumor - Report of two cases with similar morphology,” Diagnostic Pathology, vol. 2, no. 1, article no. 1, 2007.

[2] H.-U. Völker, M. Scheich, A. Zettl, R. Hagen, H. K. Müller-Hermelink, and S. Gattenlöhner, “Laryngeal inflammatory myofibroblastic tumors: Different clinical appearance and histomorphologic presentation of one entity,” Head & Neck, vol. 32, no. 11, pp. 1573–1578, 2010.

[3] E. A. Montgomery, D. D. Shuster, A. L. Burkart et al., “Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma,” The American Journal of Surgical Pathology, vol. 30, no. 12, pp. 1502–1512, 2006.

[4] C. M. Coffin, J. Watterson, J. R. Priest, and L. P. Dehner, “Extra-pulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor): a clinicopathologic and immunohistochemical study of 84 cases,” The American Journal of Surgical Pathology, vol. 19, no. 8, pp. 859–872, 1995.

[5] S. T. Saab, J. L. Hornick, C. D. Fletcher, S. J. Olson, and C. M. Coffin, “IgG4 plasma cells in inflammatory myofibroblastic tumor: Inflammatory marker or pathogenic link,” Modern Pathology, vol. 24, no. 4, pp. 606–612, 2011.

[6] M. Harel and J. H. Makari, “Paratesticular inflammatory myofibroblastic tumor in a pediatric patient,” Case Reports in Urology, vol. 2014, Article ID 303678, 4 pages, 2014.

[7] P. P. Dangle, W. P. Wang, and K. S. Pohar, "Inflammatory myofibroblastic tumor of epididymis: A case report and review of literature," World Journal of Surgical Oncology, vol. 6, article no. 119, 2008.

[8] C.-H. Yee, K.-F. To, S.-M. Hou, and C.-F. Ng, "Inflammatory Myofibroblastic Tumor of Spermatic Cord in Undescended Testis," Urology, vol. 73, no. 6, pp. 1423–e12, 2009.

[9] N. Rafeek, L. D. Joseph, S. Rajendiran, and C. D. Narayanan, "Inflammatory myofibroblastic tumor of spermatic cord," International Journal of Surgery Case Reports, vol. 3, no. 12, pp. 618–621, 2012.

[10] R. A. Hickman, M. Alexander, J. Provet, J. Melamed, and F.-M. Deng, "Inflammatory myofibroblastic tumour of the testis with confirmed anaplastic lymphoma kinase gene rearrangement," Histopathology, vol. 68, no. 7, pp. 1109–1111, 2016.

[11] M. Nistal, P. Gonzalez-Peramato, A. Serrano, M. Reyes-Mugica, and M. M. Cajaiba, "Primary intratesticular spindle cell tumors: Interdigitating dendritic cell tumor and inflammatory myofibroblastic tumor," International Journal of Surgical Pathology, vol. 19, no. 1, pp. 104–109, 2011.

[12] Z. Orozs and I. Besznyák, “Diffuse inflammatory pseudotumor of the testis, the epididymis and the spermatic cord,” Pathology & Oncology Research, vol. 1, no. 1, pp. 75–79, 1995.

[13] H. Yamamoto, A. Yoshida, K. Taguchi et al., "ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumors," Histopathology, vol. 69, no. 1, pp. 72–83, 2016.

[14] B. Lawrence, A. Perez-Atayde, M. K. Hibbard et al., "TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors," The American Journal of Pathology, vol. 157, no. 2, pp. 377–384, 2000.

[15] H. Fujita, A. Yoshida, H. Taniguchi, H. Kaitai, and S. Sekine, "Adult-onset inflammatory myofibroblastic tumour of the stomach with a TFG-ROSI fusion," Histopathology, vol. 66, no. 4, pp. 610–612, 2015.

[16] J. M. Guilemany, L. Alós, I. Alobid, M. Bernal-Sprekels, and A. Cardesa, "Inflammatory myofibroblastic tumor in the larynx: Clinicopathologic features and histogenesis," Acta Oto-Laryngologica, vol. 125, no. 2, pp. 215–219, 2005.